#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Superficial vein thrombosis Oesophageal adenocarcinoma Ocular myasthenia Congenital nephrogenic diabetes insipidus Fms-like tyrosine kinase 3 positive Spinal cord injury Biliary cancer metastatic Niemann-Pick disease Nephrotic syndrome Familial dilated cardiomyopathy Gaucher's disease type III Iron overload Neuroendocrine tumour Angiosarcoma non-metastatic Metastatic gastric cancer More trials…

    Learn about Rare Diseases

    Pelizaeus-Merzbacher disease – Trials in Disease Breast angiosarcoma metastatic – Basic Information Leukoencephalopathy – Treatment Angiosarcoma recurrent – Diagnostics Mantle cell lymphoma stage IV – Trials in Disease Glomerulonephritis rapidly progressive – Diagnostics Medulloblastoma recurrent – Diagnostics Idiopathic inflammatory myopathy – Basic Information Lymphatic malformation – Treatment Pulmonary sarcoidosis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Reboxetine Ima203Cd8 Sibeprenlimab Folic Acid Mecasermin Rinfabate Cimetidine GSK5733584 Clofazimine Pegenzileukin Mk-6194 Isoprenaline Hydrochloride Riociguat Cevostamab Cx-044933 Imgn151 Copper (64Cu) Chloride Albaconazole IPN01195 Fosphenytoin Sodium Donepezil More therapies…

    Learn about Your Condition

    Lymphangioleiomyomatosis Hypocalcaemia Hyperthyroidism Cholangitis sclerosing Irritable bowel syndrome Macular degeneration Dyskinesia Diabetic ketoacidosis Graft versus host disease EGFR gene mutation Muscle strain Paedophilia Diphtheria Anal incontinence Systemic scleroderma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Lithuania

  • A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • BLEXIMENIB
    Austria Belgium Denmark Estonia Finland Germany +8
  • A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +10
  • A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9
  • A study testing duvakitug for patients with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9
  • Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Blinatumomab
    Austria Czechia Denmark Finland France Germany +7
  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Daunorubicin Hydrochloride
    • Idarubicin Hydrochloride
    • Revumenib
    Austria Belgium Czechia France Germany Greece +7
Previous Page
1 2 3 4 5 … 41
Next Page

Find Clinical Trials in Your Selected Region and City

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Pembrolizumab Cisplatin Etoposide Methotrexate Cytarabine Dexamethasone Risankizumab Hydrocortisone Efgartigimod Alfa Carboplatin Lenalidomide Olaparib Paclitaxel Sodium Chloride Apixaban Venetoclax Prednisolone Oxaliplatin Prednisone Mycophenolate Mofetil Upadacitinib Fludarabine Phosphate Azacitidine Duvakitug Barzolvolimab Durvalumab Adalimumab Blinatumomab Pemetrexed Fluorouracil Show more

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

Acquired antithrombin III deficiency Acromegaly Acute coronary syndrome Acute graft versus host disease Acute leukaemia Acute lymphocytic leukaemia Acute myeloid leukaemia Acute myocardial infarction Acute respiratory distress syndrome Adenocarcinoma gastric Adrenogenital syndrome Allogenic stem cell transplantation Alport's syndrome Anaemia Antibiotic therapy Arteriosclerosis Asthma Atrial fibrillation Axial spondyloarthritis B-cell lymphoma recurrent B-cell lymphoma refractory B-cell type acute leukaemia Bladder cancer Bronchiectasis Cardiac amyloidosis Cardiac failure Cardiac failure chronic Cardiovascular disorder Cerebrovascular accident prophylaxis Chronic graft versus host disease Chronic kidney disease Chronic lymphocytic leukaemia Chronic obstructive pulmonary disease Chronic spontaneous urticaria Coagulation factor X level Cold urticaria Colitis ulcerative Colorectal cancer stage IV Conjunctivitis allergic Contraception COVID-19 Critical illness Crohn's disease Cystic fibrosis Dermatitis atopic Diabetic foot infection Dry eye Dyslipidaemia EGFR gene mutation Embolism Embolism venous Endometrial cancer Endometrial cancer metastatic Endometrial cancer recurrent Erosive oesophagitis Erythema migrans Factor IX deficiency Factor VIII deficiency Fallopian tube cancer Familial hypertriglyceridaemia Gastric cancer Glioblastoma multiforme Glomerulonephritis Gout Haemophilia A without inhibitors Haemophilia B without inhibitors Heparin resistance Hereditary haemorrhagic telangiectasia Hidradenitis Hormone-refractory prostate cancer Hyperchylomicronaemia Hypertension Hypertriglyceridaemia Idiopathic inflammatory myopathy IgA nephropathy Immune thrombocytopenia Infection prophylaxis Influenza Iron deficiency Iron deficiency anaemia Ischaemic stroke Juvenile idiopathic arthritis Lupus nephritis Macular oedema Major depression Malignant melanoma stage II Malignant melanoma stage III Metastatic gastric cancer Metastatic malignant melanoma Microsatellite instability cancer Migraine Multifocal motor neuropathy Multiple sclerosis Multiple sclerosis relapse Myelodysplastic syndrome Myelodysplastic syndrome with excess blasts Myelofibrosis Neoplasm Neoplasm malignant Neovascular age-related macular degeneration Nephrogenic anaemia Nephropathy Neuroblastoma Neurogenic bladder Non-small cell lung cancer Non-small cell lung cancer metastatic Noonan syndrome Oesophageal adenocarcinoma Oesophageal cancer metastatic Oesophageal carcinoma Ovarian cancer Paroxysmal nocturnal haemoglobinuria Partial seizures Peritoneal cancer index Plasma cell myeloma Pneumonia Primary biliary cholangitis Primary myelofibrosis Progressive relapsing multiple sclerosis Prostate cancer Prostate cancer metastatic Proteinuria Psoriatic arthropathy Pulmonary arterial hypertension Pyelonephritis acute Relapsing multiple sclerosis Relapsing-remitting multiple sclerosis Retinal vein occlusion Rheumatoid arthritis Rhinitis allergic Schizophrenia Secondary progressive multiple sclerosis Short stature Sjogren's syndrome Skin bacterial infection Small cell lung cancer Small cell lung cancer limited stage Small for dates baby Squamous cell carcinoma of head and neck Status epilepticus Still's disease Systemic lupus erythematosus Systemic scleroderma Thrombosis prophylaxis Transient ischaemic attack Turner's syndrome Type 2 diabetes mellitus Urinary tract infection Varicella

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!